5-HTP 100 mg
On sale on the US market (according to the DSLD)
Jarrow Formulas, food supplement from the US market
5-HTP 100 mg (Jarrow Formulas), a food supplement au code-barres 790011150435, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
No point flagged by the rules we apply.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Jarrow Formulas
- Barcode
- 790011150435
- Form
- Capsule
- One serving
- 1 capsule
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Microcrystalline Cellulose, Hydroxypropylmethylcellulose, Water, Magnesium Stearate, Silicon Dioxide
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| 5-HTP | Amino acid | 100 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: 5-HTP 100 mg
Entered into DSLD on 19 May 2022. Withdrawn from the US market on 4 January 2024 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 22 January 2021. Withdrawn from the US market on 15 October 2021 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 22 December 2019. Withdrawn from the US market on 4 January 2024 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 25 April 2019. Withdrawn from the US market on 4 May 2019 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 25 September 2015. Withdrawn from the US market on 13 February 2019 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 25 April 2014. Withdrawn from the US market on 3 June 2015 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 24 January 2014. Withdrawn from the US market on 31 December 2013 (according to the DSLD).Same active composition.
Official label: 5-HTP 100 mg
Entered into DSLD on 26 April 2012. Withdrawn from the US market on 13 December 2013 (according to the DSLD).Same active composition.
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- 5-HTP
Read the warning, when it applies and the studies cited
5-HTP
Route of administration: Oral
Cautions and warnings
Condition of application: All uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking carbidopa or health products with serotonergic activity such as mood balance supplements, cough medication containing dextromethorphan, pain killers or medications for nausea or migraine (Mayo Clinic Staff 2022; Patel and Marzella 2017; Turner et al 2006).
Sources cited by Health Canada (3)
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Case report
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Review article
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product exercise caution while driving or using machinery, as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (1)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollings CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All uses (excluding weight management).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Condition of application: Weight management.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Condition of application: Healthy mood balance; Fibromyalgia symptoms.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a psychological disorder such as anxiety or depression.
Contraindications
Condition of application: All uses.
Do not use if you have scleroderma (Lampert et al. 1992; Sternberg et al. 1980).
Sources cited by Health Canada (2)
- Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Case report
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Clinical trial
Do not use if you are taking antidepressants (Mayo Clinic Staff 2022; Patel and Marzella 2017).
Sources cited by Health Canada (2)
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Case report
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Condition of application: Weight management.
Do not use if you are pregnant (HC 2010).
Sources cited by Health Canada (2)
- HC 2010: Health Canada: Prenatal Nutrition Guidelines for health Professionals: Gestational weight gain [Accessed 2024 April 7]. Available from: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-eng.pdf
- SC 2010 : Santé Canada : Lignes directrices sur la nutrition pendant la grossesse à l'intention des professionnels de la santé : Gain de poids pendant la grossesse. [Consulté le 7 avril 2024]. Disponible à : https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/fn-an/alt_formats/pdf/nutrition/prenatal/ewba-mbsa-fra.pdf
Known adverse reactions
When using this product you may experience gastrointestinal discomfort/disturbances (Turner et al. 2006; Byerley et al. 1987).
Sources cited by Health Canada (2)
- Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. Journal of Clinical Psychopharmacology 1987;7(3):127-137. PubMed Clinical trial
- Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & Therapeutics 2006;109(3):325-338. PubMed Review article
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if you experience skin hardening, pain or stiffness of muscles or joints, tremors, agitation/confusion, or an increased heart rate (Boyer 2023; Varga 2023; Mayo Clinic Staff 2022; Patel and Marzella 2017; Das et al. 2004; Erner et al. 2003; Lampert et al. 1992; Sternberg et al. 1980).
Sources cited by Health Canada (8)
- Boyer EW. Serotonin syndrome (serotonin toxicity). UpToDate 2023 [Accessed 2023 October 18]. Available from: Available from : https://www.uptodate.com/.
- Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicology Letters 2004;150(1):111-122. PubMed Case report
- Erner RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin Syndrome and Other Serotonergic Disorders. Pain Medicine 2003;4(1): 63-74.
- Lampert A, Joly P, Thomine E, Ortoli JC, Lauret P. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam]. Annales de Dermatologie et de Vénéréologie 1992;119(3):209-211 (in French). PubMed Case report
- Mayo Clinic Staff. Serotonin Syndrome. Rochester (MN): Mayo Foundation for Medical Education and Research; 2022. [Accessed 2023 March 07]. Available from: https://www.mayoclinic.org/diseases-conditions/serotonin-syndrome/symptoms-causes/syc-20354758.
- Patel YA, Marzella N. Dietary supplement-drug interaction-induced serotonin syndrome progressing to acute compartment syndrome. American Journal of Case Reports 2017; 18:926-930. PubMed Case report
- Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. New England Journal of Medicine 1980;303(14):782-787. PubMed Clinical trial
- Varga J. Clinical manifestations and diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate 2023 [Accessed 2023 October 18]. Available from : https://www.uptodate.com/.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Jarrow Formulas
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “5-HTP 100 mg (Jarrow Formulas): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/790011150435-5-htp-100-mg-jarrow-formulas, updated 24 January 2024.